Business Wire

Sunovion Submits New Drug Application for SUN-101/eFlow ® to the FDA for the Treatment of Patients with Chronic Obstructive Pulmonary Disease (COPD)

MARLBOROUGH, Mass.-- (BUSINESS WIRE)-- Sunovion Pharmaceuticals Inc. (Sunovion) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ...
Business Wire

Efficio Launches First eFlow Software Application Module – Spend Analytics

LONDON--(BUSINESS WIRE)--Efficio, the procurement experts, today launched Spend Analytics, the first product in a suite of custom procurement modules that make up the proprietary technology platform ...
Reuters

Sumitomo Dainippon Pharma unit receives Complete Response Letter from FDA for SUN-101/eFlow® New Drug Application for chronic obstructive pulmonary disease

* Says its US-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for SUN-101 ...